115643-59-9

Basic information

• Product Name: 2-AMINO-6-FLUOROBENZAMIDE
• Synonyms: 2-AMINO-6-FLUOROBENZAMIDE;Benzamide, 2-amino-6-fluoro- (9CI);2-Carbamoyl-3-fluoroaniline, 2-(Aminocarbonyl)-3-fluoroaniline
• CAS NO: 115643-59-9
• Molecular Formula: C₇H₇FN₂O
• Molecular Weight: 154.14
• Product Categories: AMIDE
• Mol File: 115643-59-9.mol

Chemical Properties

• Melting Point: 115 °C
• Boiling Point: 256.953 °C at 760 mmHg
• Flash Point: 109.202 °C
• Appearance: /
• Density: 1.345 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.04±0.50(Predicted)
• CAS DataBase Reference: 2-AMINO-6-FLUOROBENZAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-AMINO-6-FLUOROBENZAMIDE(115643-59-9)
• EPA Substance Registry System: 2-AMINO-6-FLUOROBENZAMIDE(115643-59-9)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 36/37/38-22
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 115643-59-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-AMINO-6-FLUOROBENZAMIDE is used as a building block for the synthesis of new drugs due to its structural properties that can be tailored for specific therapeutic applications. Its potential in drug development is attributed to the ability to modify its chemical structure to target various biological pathways and mechanisms.
Used in Agrochemical Industry:
In the agrochemical sector, 2-AMINO-6-FLUOROBENZAMIDE serves as a precursor in the development of new agrochemicals, leveraging its structural attributes to create compounds that can address specific needs in agriculture, such as pest control and crop protection.
Used in Dye and Pigment Production:
2-AMINO-6-FLUOROBENZAMIDE is utilized as an intermediate in the production of dyes and pigments, capitalizing on its chemical composition to create a diverse range of colorants for various applications, including textiles, plastics, and printing inks.
Used in Industrial Processes:
The unique properties of the fluorine group in 2-AMINO-6-FLUOROBENZAMIDE make it an important component in a wide array of industrial processes, where its reactivity and stability contribute to the efficiency and performance of the end products.

Upstream product

• 77326-36-4 2-amino-6-fluorobenzonitrile 
• 79544-29-9 2-fluoro-6-iodobenzonitrile 
• 78755-94-9 5-fluoro-2H-benzo[d][1,3]-oxazine-2,4(1H)-dione 
• 434-76-4 2-amino-6-fluorobenzoic acid 

Downstream Products

• 437998-39-5 2-(4-bromo-butyrylamino)-6-fluoro-benzamide 
• 436-72-6 5-fluoroquinazolin-4(3H)-one 
• 1098337-02-0 5-fluoro-2-(4-(trifluoromethyl)phenyl)quinazolin-4(1H)-one 
• 1098337-00-8 5-fluoro-2-(2,4-dihydroxyphenyl)quinazolin-4(1H)-one 
• 1379304-63-8 C₉H₉FN₂O₂ 
• 1098337-01-9 5-fluoro-2-(4-fluorophenyl)quinazolin-4(1H)-one 
• 869299-02-5 ethyl ((2-(aminocarbonyl)-3-fluorophenyl)amino)(oxo)acetate 
• 1241915-00-3 (R,S)-5-fluoro-2-((4-fluorophenyl)(hydroxyl)methyl)quinazolin-4-ol 
• 1431758-13-2 C₁₁H₁₀FNO 
• 1571119-70-4 2-phenyl-5-fluoro-2,3-dihydroquinazolin-4(1H)-one 
• 1098336-86-7 5-fluor-2-phenylquinazolin-4(3Η)-one 

Relevant articles and documents

Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex

Bromodomain containing proteins PB1, SMARCA4, and SMARCA2 are important components of SWI/SNF chromatin remodeling complexes. We identified bromodomain inhibitors that target these proteins and display unusual binding modes involving water displacement from the KAc binding site. The best compound binds the fifth bromodomain of PB1 with a KD of 124 nM, SMARCA2B and SMARCA4 with KD values of 262 and 417 nM, respectively, and displays excellent selectivity over bromodomains other than PB1, SMARCA2, and SMARCA4.

Design, Synthesis, and Potency of Pyruvate Dehydrogenase Complex E1 Inhibitors against Cyanobacteria

Safe and effective algaecides are needed to control agriculturally and environmentally significant algal species. Four series (6, 10, 17, and 21) of 29 novel 4-aminopyrimidine derivatives were rationally designed and synthesized. A part of 10, 17, and 21 displayed potent inhibition of Escherichia coli pyruvate dehydrogenase complex E1 (E. coli PDHc-E1) (IC50 = 2.12-18.06 μM) and good inhibition of Synechocystis sp. PCC 6803 (EC50 = 0.7-7.1 μM) and Microcystis sp. FACH 905 (EC50 = 3.7-7.6 μM). The algaecidal activity of these compounds positively correlated with their inhibition of E. coli PDHc-E1. In particular, 21l and 10b exhibited potent algaecidal activity against PCC 6803 (EC50 = 0.7 and 0.8 μM, respectively), values that were 2-fold increased compared to that of copper sulfate (EC50 = 1.8 μM), and showed the best inhibition of cyanobacterium PDHc-E1 (IC50 = 5.10 and 6.06 μM, respectively). 17h and 21e, the best inhibitors of E. coli PDHc-E1, were studied by molecular docking, site-directed mutagenesis, and enzymatic assays. These results revealed that the improved inhibition of novel inhibitors compared with that of the lead compound I was due to the formation of a new hydrogen bond with Leu264 at the active site of E. coli PDHc-E1. The results proved the great potential to obtain effective algaecides via the rational design of PDHc-E1 inhibitors. [Figure Presented]

6-Fluorophenylbenzohydrazides inhibit Mycobacterium tuberculosis growth through alteration of tryptophan biosynthesis

A major constraint in reducing tuberculosis epidemic is the emergence of strains resistant to one or more of clinically approved antibiotics, which emphasizes the need of novel drugs with novel targets. Genetic knockout strains of Mycobacterium tuberculosis (Mtb) have established that tryptophan (Trp) biosynthesis is essential for the bacterium to survive in vivo and cause disease in animal models. An anthranilate-like compound, 6-FABA, was previously shown to synergize with the host immune response to Mtb infection in vivo. Herein, we present a class of anthranilate-like compounds endowed with good antimycobacterial activity and low cytotoxicity. We show how replacing the carboxylic moiety with a hydrazide led to a significant improvement in both activity and cytotoxicity relative to the parent compound 6-FABA. Several new benzohydrazides (compounds 20–31, 33, 34, 36, 38 and 39) showed good activities against Mtb (0.625 ≤ MIC≤6.25 μM) and demonstrated no detectable cytotoxicity against Vero cell assay (CC50 ≥ 1360 μM). The target preliminary studies confirmed the hypothesis that this new class of compounds inhibits Trp biosynthesis. Taken together, these findings indicate that fluorophenylbenzohydrazides represent good candidates to be assessed for drug discovery.

ERBB RECEPTOR INHIBITORS

Disclosed are compounds inhibiting ErbBs (e. g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer.

POLY-ADP RIBOSE POLYMERASE (PARP) INHIBITORS

The present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier or diluent and a compound represented by the following structural formula: The present invention is also related a method of treating a subject with a disease which can be ameliorated by inhibition of poly(ADP-ribose)polymerase (PARP). The definitions of the variables are provided herein.

On the Synthesis and Reactivity of 2,3-Dihydropyrrolo[1,2- a ]quinazolin-5(1 H)-ones

An improved, scalable synthetic route to the quinazolinone natural product 2,3-dihydropyrrolo[1,2-a]quinazolin-5(1H)-one is reported. The applicability of this method to analogue synthesis and the synthesis of related natural products is explored. Finally, reactivity of the scaffold to a variety of electrophilic reagents, generating products stereoselectively, is reported.

FACTOR IXA INHIBITORS

The present invention provides a compound of Formula (I) (structurally represented) wherein R1, R2, R3 and R4 are independently H or C1-6 alkyl, provided that when R1, R2, and R3 are H, R4 is C1-6 alkyl, and when R1, R2, and R4 are H, R3 is C1-6 alkyl, and when R1, R3, and R4 are H, R2 is C1-6 alkyl, and when R2, R3, and R4 are H, R1 is C1-6 alkyl; and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

FACTOR IXa INHIBITORS

The present invention provides a compound of Formula (I) wherein A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more of said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

Super acid catalysed sequential hydrolysis/cycloisomerization of o-(acetylenic)benzamides under microwave condition: Synthesis, antinociceptive and antiinflammatory activity of substituted isocoumarins

Synthesis of isocoumarins and related compounds via triflic acid promoted hydrolysis/cyclization sequence of 2-(alkynyl)benzamides under microwave condition was achieved. The substrate scope of the reaction was broad to include not only aromatic but also

Efficient and practical transition metal-free catalytic hydration of organonitriles to amides

K2CO3 can act as an efficient catalyst for the hydration of organonitriles in aqueous conditions assisted by microwave irradiation, which represents an inexpensive, practical, atom-economical, and straightforward transition metal-free protocol to various amides.